Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 7 August 1987:
Vol. 237. no. 4815, pp. 639 - 642
DOI: 10.1126/science.3299709
Prev | Table of Contents | Next

Articles

Science, Vol 237, Issue 4815, 639-642
Copyright © 1987 by American Association for the Advancement of Science

articles

Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications

SL Hoffman, CN Oster, CV Plowe, GR Woollett, JC Beier, JD Chulay, RA Wirtz, MR Hollingdale, and M Mugambi

The first human vaccines against the malaria parasite have been designed to elicit antibodies to the circumsporozoite protein of Plasmodium falciparum. However, it is not known whether any level of naturally acquired antibodies to the circumsporozoite protein can predict resistance to Plasmodium falciparum malaria. In this study, 83 adults in a malaria-endemic region of Kenya were tested for circumsporozoite antibodies and then treated for malaria. They were monitored for the development of new malaria infections for 98 days. Antibody levels, as determined by four assays in vitro, were indistinguishable between the 60 individuals who did and the 23 who did not develop parasitemia during follow-up, and there was no apparent relation between day of onset of parasitemia and level of antibodies to circumsporozoite protein. Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
World Malaria Day 2009: What Malaria Knows about the Immune System That Immunologists Still Do Not.
S. K. Pierce and L. H. Miller (2009)
J. Immunol. 182, 5171-5177
   Abstract »    Full Text »    PDF »
Acquired Immunity to Malaria.
D. L. Doolan, C. Dobano, and J. K. Baird (2009)
Clin. Microbiol. Rev. 22, 13-36
   Abstract »    Full Text »    PDF »
RELATIONSHIP BETWEEN THE ENTOMOLOGIC INOCULATION RATE AND THE FORCE OF INFECTION FOR PLASMODIUM FALCIPARUM MALARIA..
T. SMITH, N. MAIRE, K. DIETZ, G. F. KILLEEN, P. VOUNATSOU, L. MOLINEAUX, and M. TANNER (2006)
Am J Trop Med Hyg 75, 11-18
   Abstract »    Full Text »    PDF »
Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-Resistant Plasmodium falciparum in Gambian Children..
M. Pinder, C. J. Sutherland, F. Sisay-Joof, J. Ismaili, M. B. B. McCall, R. Ord, R. Hallett, A. A. Holder, and P. Milligan (2006)
Infect. Immun. 74, 2887-2893
   Abstract »    Full Text »    PDF »
Antigenic Diversity and Immune Evasion by Malaria Parasites.
M. U. Ferreira, M. da Silva Nunes, and G. Wunderlich (2004)
Clin. Vaccine Immunol. 11, 987-995
   Full Text »    PDF »
Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa.
C. C. John, R. A. O'Donnell, P. O. Sumba, A. M. Moormann, T. F. de Koning-Ward, C. L. King, J. W. Kazura, and B. S. Crabb (2004)
J. Immunol. 173, 666-672
   Abstract »    Full Text »    PDF »
Progress in the development of recombinant and synthetic blood-stage malaria vaccines.
S. Mahanty, A. Saul, and L. H. Miller (2003)
J. Exp. Biol. 206, 3781-3788
   Abstract »    Full Text »    PDF »
Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.
T. C. Luke and S. L. Hoffman (2003)
J. Exp. Biol. 206, 3803-3808
   Abstract »    Full Text »    PDF »
Successful Induction of CD8 T Cell-Dependent Protection Against Malaria by Sequential Immunization with DNA and Recombinant Poxvirus of Neonatal Mice Born to Immune Mothers.
M. Sedegah, M. Belmonte, J. E. Epstein, C.-A. Siegrist, W. R. Weiss, T. R. Jones, M. Lu, D. J. Carucci, and S. L. Hoffman (2003)
J. Immunol. 171, 3148-3153
   Abstract »    Full Text »    PDF »
Unique T Cell Effector Functions Elicited by Plasmodium falciparum Epitopes in Malaria-Exposed Africans Tested by Three T Cell Assays.
K. L. Flanagan, E. A. M. Lee, M. B. Gravenor, W. H. H. Reece, B. C. Urban, T. Doherty, K. A. Bojang, M. Pinder, A. V. S. Hill, and M. Plebanski (2001)
J. Immunol. 167, 4729-4737
   Abstract »    Full Text »    PDF »
HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles.
D. L. Doolan, S. Southwood, R. Chesnut, E. Appella, E. Gomez, A. Richards, Y. I. Higashimoto, A. Maewal, J. Sidney, R. A. Gramzinski, et al. (2000)
J. Immunol. 165, 1123-1137
   Abstract »    Full Text »    PDF »
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against Plasmodium falciparum Malaria.
J. A. Stoute, M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, M. Marchand, et al. (1997)
N. Engl. J. Med. 336, 86-91
   Abstract »    Full Text »    PDF »
Identification and Characterization of the Protective Hepatocyte Erythrocyte Protein 17kDa Gene of Plasmodium yoelii, homolog of Plasmodium falciparum Exported Protein 1.
D. L. Doolan, R. C. Hedstrom, W. O. Rogers, Y. Charoenvit, M. Rogers, P. d. l. Vega, and S. L. Hoffman (1996)
J. Biol. Chem. 271, 17861-17868
   Abstract »    Full Text »    PDF »
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein.
S Khusmith, Y Charoenvit, S Kumar, M Sedegah, R. Beaudoin, and S. Hoffman (1991)
Science 252, 715-718
   Abstract »    PDF »
Limited immunological recognition of critical malaria vaccine candidate antigens.
M. Good, L. Miller, S Kumar, I. Quakyi, D Keister, J. Adams, B Moss, J. Berzofsky, and R Carter (1988)
Science 242, 574-577
   Abstract »    PDF »
NATURAL IMMUNITY TO MALARIA AND VACCINE DEVELOPMENT.
(1987)
Journal Watch (General) 1987, 8
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)